BR112017022553A2 - métodos e materiais para matar células infectadas por hiv - Google Patents

métodos e materiais para matar células infectadas por hiv

Info

Publication number
BR112017022553A2
BR112017022553A2 BR112017022553A BR112017022553A BR112017022553A2 BR 112017022553 A2 BR112017022553 A2 BR 112017022553A2 BR 112017022553 A BR112017022553 A BR 112017022553A BR 112017022553 A BR112017022553 A BR 112017022553A BR 112017022553 A2 BR112017022553 A2 BR 112017022553A2
Authority
BR
Brazil
Prior art keywords
methods
materials
infected cells
hiv infected
killing hiv
Prior art date
Application number
BR112017022553A
Other languages
English (en)
Inventor
M Nguyen Amy
D Badley Andrew
Dai Haiming
H Kaufmann Scott
Pang Yuan-Ping
Original Assignee
Mayo Found Medical Education & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Found Medical Education & Res filed Critical Mayo Found Medical Education & Res
Publication of BR112017022553A2 publication Critical patent/BR112017022553A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

a presente invenção refere-se aos métodos e aos materiais envolvidos na matança de células infectadas com hiv (por exemplo, células t cd4). por exemplo, os métodos e os materiais para usar um ou mais inibidores de bcl-2 (por exemplo, abt-199) por si só ou em combinação com um ou mais agentes capazes de reativar o hiv (por exemplo, agente de reversão de latência) para matar as células infectadas por hiv (por exemplo, células t cd4) são fornecidos.
BR112017022553A 2015-04-20 2016-04-20 métodos e materiais para matar células infectadas por hiv BR112017022553A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562149873P 2015-04-20 2015-04-20
PCT/US2016/028419 WO2016172194A1 (en) 2015-04-20 2016-04-20 Methods and materials for killing hiv infected cells

Publications (1)

Publication Number Publication Date
BR112017022553A2 true BR112017022553A2 (pt) 2018-07-17

Family

ID=57144198

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017022553A BR112017022553A2 (pt) 2015-04-20 2016-04-20 métodos e materiais para matar células infectadas por hiv

Country Status (5)

Country Link
US (2) US20180161347A1 (pt)
EP (1) EP3285775B1 (pt)
CN (1) CN108025015B (pt)
BR (1) BR112017022553A2 (pt)
WO (1) WO2016172194A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016137844A1 (en) 2015-02-23 2016-09-01 Mayo Foundation For Medical Education And Research Methods and materials for treating human immunodeficiency virus infections
WO2016172194A1 (en) 2015-04-20 2016-10-27 Mayo Foundation For Medical Education And Research Methods and materials for killing hiv infected cells
US20200261445A1 (en) * 2017-09-29 2020-08-20 The George Washington University Use of senolytic agents to eliminate persistent hiv reservoirs
MX2020007392A (es) * 2018-01-10 2020-10-14 Recurium Ip Holdings Llc Compuestos de benzamida.
WO2021113632A1 (en) * 2019-12-04 2021-06-10 The Methodist Hospital System A combination therapy approach to eliminate hiv infections

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976786A (en) 1995-12-29 1999-11-02 National Jewish Medical And Research Center Screening methods for the identification of compounds that modulate apoptosis in immunodeficiency virus infected cells
US20030232738A1 (en) 1998-04-20 2003-12-18 National Jewish Medical And Research Center Method and composition for increasing CD4+ T lymphocyte immune responsiveness
AU5446499A (en) 1998-08-31 2000-03-21 Kyowa Hakko Kogyo Co. Ltd. Apoptosis inducing agents
WO2000033654A1 (en) 1998-12-04 2000-06-15 University Of Maryland Biotechnology Institute Use of protease inhibitors to modulate cellular pathways, immunity and therapies associated therewith
WO2006017346A1 (en) 2004-07-13 2006-02-16 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH A ND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER Treatment of viral infections by means o proteasome inhibitors
US8557812B2 (en) 2004-08-20 2013-10-15 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof
US8247613B2 (en) * 2006-04-17 2012-08-21 The J. David Gladstone Institutes Methods and compositions for the synergistic activation of latent HIV
WO2008124129A2 (en) 2007-04-09 2008-10-16 University Of Massachusetts Treating hiv with a m-csf effector kinase inhibitor like imatinib
WO2009036051A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors containing a zinc binding moiety
US8728458B2 (en) 2009-04-30 2014-05-20 The Regents Of The University Of California Combination anti-HIV vectors, targeting vectors, and methods of use
WO2011089166A1 (en) 2010-01-19 2011-07-28 Virologik Gmbh Semicarbazone proteasome inhibitors for treating hiv and hepatitis infection
CN102690326B (zh) * 2012-05-29 2014-04-02 武汉大学 具有抗艾滋病毒活性的棉酚衍生物及其制备
EP2970262A1 (en) * 2013-03-11 2016-01-20 AbbVie Inc. Bromodomain inhibitors
WO2016137844A1 (en) 2015-02-23 2016-09-01 Mayo Foundation For Medical Education And Research Methods and materials for treating human immunodeficiency virus infections
WO2016172194A1 (en) 2015-04-20 2016-10-27 Mayo Foundation For Medical Education And Research Methods and materials for killing hiv infected cells

Also Published As

Publication number Publication date
EP3285775B1 (en) 2020-04-15
US20180161347A1 (en) 2018-06-14
US20210379086A1 (en) 2021-12-09
EP3285775A1 (en) 2018-02-28
EP3733191A1 (en) 2020-11-04
CN108025015A (zh) 2018-05-11
WO2016172194A1 (en) 2016-10-27
EP3285775A4 (en) 2018-11-14
US11938098B2 (en) 2024-03-26
CN108025015B (zh) 2021-11-09

Similar Documents

Publication Publication Date Title
CL2018000684A1 (es) Moduladores de la proteína de núcleo de la hepatitis b.
BR112017007636A2 (pt) métodos para a preparação de ribosídeos
BR112017028318A2 (pt) compostos antibacterianos
CL2015003615A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
EA201990043A1 (ru) Антибактериальные соединения
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
CL2018002334A1 (es) Moduladores de complementos factor b (divisional solicitud 201600606)
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
BR112017022553A2 (pt) métodos e materiais para matar células infectadas por hiv
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
CU20160187A7 (es) (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobencil)carbamoil)-2,3,4,5,7,9,13, 13a-octahidro-2,5-metanopirido[1',2':4,5]pirazino[2,1-b][1,3]oxazepin-8-olato de sodio
GT201500020A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
BR112016029318A2 (pt) tratamento de mielomas
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
BR112022000503A2 (pt) Compostos úteis para tratar infecções por vírus influenza
CO2019009215A2 (es) Sal hemi-sulfato de nucleótido para el tratamiento del virus de la hepatitis c
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
BR112019004496A2 (pt) estabilizantes de mastócitos para tratamento de hipercitocinemia e infecção viral
CL2018000158A1 (es) Composiciones y métodos para inhibir la expresión del gen alas1 (divisional de solicitud 20160772)
EA201891783A1 (ru) Композиция для растворения аморфных дитиазинов и способ ее применения
CL2016000300A1 (es) Métodos terapéuticos
CL2017000151A1 (es) Derivados de piridona
BR112018008911A2 (pt) composições compreendendo vetores lentivirais que expressam il-12 e métodos de uso das mesmas
BR112017019750A2 (pt) processo para preparação de uma forma cristalina de menaquinol, forma cristalina de menaquinol, processo para preparação de uma forma sólida do menaquinol, composição farmacêutica ou nutracêutica e uso da forma cristalina de menaquinol

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]